Streetbeat News

CSBTF

Kuros Biosciences AG

http://www.kuros.ch/

CEO

Joost de Bruijn

Industry

Research and Development in Biotechnology

Open

25.30

Mkt cap

911M

Volume

700

High

25.53

P/E Ratio

-91.18

52-wk high

36.10

Low

25.23

Div yield

N/A

52-wk low

3.85

Kuros Biosciences has received FDA 510K clearance for its MagnetOs Granules for interbody use, marking the third product in the MagnetOs portfolio to gain such approval. Additionally, Kuros has obtained regulatory clearance for both MagnetOs Granules and MagnetOs Putty in New Zealand and will launch these products through an exclusive distribution agreement with Vortek Spine Limited.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:51 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.